RxDoctor Payments Data

Bradley Waller, MD

Family Medicine · Maquoketa, IANPI 1609433796

Payments from drug & device makers

$3,616in general payments, 2019–2025

Across 200 payments — averaging $18.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$730
  • Amgen$538
  • AstraZeneca$478
  • Novo Nordisk$346
  • Lilly USA, LLC$263
  • Astellas Pharma US Inc$208
  • plus $1K from 17 others

What the payments were for

  • Food & beverage$3,55098%
  • Education$662%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,616 in reported general payments places this provider in the 90th percentile of 1,357 family medicine providers in Iowa.

See all family medicine providers in Iowa

Medicare billing

Part B allowed, 2024
$128,667
Medicare patients
352
Services billed
3,058

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban79$55,325
OzempicSemaglutide34$39,974
Breztri AerosphereBudesonide/Glycopyr/Formoterol29$18,761
Trelegy ElliptaFluticasone/Umeclidin/Vilanter23$15,915
JardianceEmpagliflozin16$14,174
Spiriva RespimatTiotropium Bromide21$11,866
JanuviaSitagliptin Phosphate44$8,377
Breo ElliptaFluticasone/Vilanterol13$5,596
SymbicortBudesonide/Formoterol Fumarate13$2,879
PaxlovidNirmatrelvir/Ritonavir17$2,858
Potassium Chloride114$2,510
Fluticasone-SalmeterolFluticasone Propion/Salmeterol23$2,415
Atorvastatin Calcium287$2,164
Rosuvastatin Calcium101$1,819
Gabapentin120$1,786

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Paxlovid$730$58,18496 claims
Novo NordiskOzempic$346$39,97434 claims
Boehringer IngelheimJardiance, Spiriva Respimat$110$26,04037 claims
AstraZenecaBreztri Aerosphere, Symbicort$478$21,64042 claims
GSKTrelegy Ellipta, Breo Ellipta$28$21,51136 claims
MerckJanuvia$40$8,37744 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,357 family medicine providers in Iowa.

Other family medicine in Maquoketa

See the full list for Iowa

Where these figures come from

Is this you, or does something look wrong? →